L. Rhamnosus ODN Fragments for Inhibiting Adipocyte Lipogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing probiotics do not effectively regulate lipogenesis, a key mechanism contributing to excessive lipid accumulation and obesity, despite the known benefits of Lactobacillus rhamnosus in inhibiting adipocyte differentiation and lipogenesis.
Innovation Solution
Identification and utilization of specific oligodeoxynucleotide (ODN) fragments from Lactobacillus rhamnosus GM-020, particularly IM3-1 (SEQ ID NO. 1) and IM3-5 (SEQ ID NO. 5), which inhibit lipogenesis by reducing the expression of lipogenesis-related genes like FAS in adipocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Lactobacillus rhamnosus is used to inhibit adipocyte differentiation and lipogenesis, then obesity prevention is improved, but the specific mechanism and effectiveness are insufficiently clarified
Solution Approach 1:
The patent extracts specific oligodeoxynucleotide (ODN) fragments from the Lactobacillus rhamnosus genome that are responsible for anti-lipogenesis activity. By isolating these functional DNA sequences (such as those containing CpG motifs), the invention identifies the precise molecular components that mediate the anti-obesity effect, thereby clarifying the mechanism while maintaining the therapeutic benefit.
2Loss of information
If oligodeoxynucleotide fragments are identified to regulate lipogenesis, then anti-obesity mechanism is clarified, but the complexity of genome analysis increases
Solution Approach 1:
The patent segments the complex bacterial genome into manageable oligodeoxynucleotide fragments for analysis. By dividing the genome into smaller sequence units and systematically analyzing their functions, the research simplifies the identification of anti-lipogenesis genes while maintaining comprehensive genome coverage.
Solution Approach 2:
The patent identifies universal CpG-containing ODN motifs that appear multiple times in the Lactobacillus rhamnosus genome and are responsible for the anti-lipogenesis effect. These universal sequences can be synthesized and applied therapeutically without requiring complete genome analysis, simplifying the approach while maintaining effectiveness.
3Manufacturing precision
If specific ODN sequences are synthesized for anti-lipogenesis, then therapeutic precision is improved, but manufacturing complexity increases
Solution Approach 1:
The patent focuses on synthesizing ODN fragments with specific sequence parameters (particularly those containing CpG motifs) that have been identified as critical for anti-lipogenesis activity. By defining specific sequence length, composition, and motif requirements, the invention standardizes the synthesis process while ensuring therapeutic precision.
Data Source
AI summary
An application based on nucleotide fragments of Lactobacillus rhamnosus GM-020, to prepare a composition for anti-lipogenesis. The Lactobacillus rhamnosus GM-020 was deposited on Dec. 18, 2003 and has the CCTCC designation number CCTCC M203098. Also provided is a composition containing Lactobacillus rhamnosus GM-020 or nucleotide fragments thereof as effective ingredients for anti-lipogenesis.